Shares of CF Pharmtech (02652) climbed sharply this morning, hitting an intraday peak with a gain exceeding 10%. As of the time of writing, the stock has pared gains to trade up 1.06% at HKD 10.47, with a turnover of HKD 42.07 million.

The company's self-developed long-acting inhaled dry powder candidate drug, ICF001, has recently secured multiple implied clinical trial approvals, covering four major indications: PAH, PH-ILD, IPF, and PPF. This makes CF Pharmtech the first domestic firm to advance such a long-acting inhaled prodrug into the clinical trial phase in China.

Notably, southbound capital has been consistently net buying recently, with holdings through the Stock Connect rising to 24.1592 million shares as of September 11, lifting the stake to 7.45%.

Dr. Liang Wenqing, the company's chairman and executive director, previously stated: "The clinical development approvals for ICF001 across four indications mark a significant milestone in CF Pharmtech's transformation from a complex inhalation platform to a global innovative asset. Positive clinical data from international peers have already demonstrated that long-acting inhaled prodrugs can become a next-generation therapeutic approach with substantial global commercial potential."